Department of Neurology

USF Department of Neurology’s Clinical Trials

  • Amyotrophic Lateral Sclerosis

    Biogen Idec – ALS (Amyotrophic Lateral Sclerosis)  – Currently Enrolling Methodology Study of Novel Outcome Measures to Assess Progression of ALS   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
    Cytokinetics, Inc. – ALS (Amyotrophic Lateral Sclerosis)Currently Enrolling   A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031)   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
    Cytokinetics, Inc. – ALS (Amyotrophic Lateral Sclerosis) Ongoing Not Enrolling A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
  • Ataxia & Movement Disorders

    FA – ALCAR – Currently Enrolling

    The purpose of this study is to learn how treatment with acetyl-L-carnitine (ALCAR) will affect the hearts of patients with Friedreich's Ataxia as well as how it may affect other symptoms of Friedreich's Ataxia such as difficulties with balance, walking, or upper arm function.

     For more information please visit the website at https://clinicaltrials.gov/ct2/show/NCT01921868

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    FA – Reata – Currently Enrolling

    This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone (RTA 408) in the treatment of patients with Friedreich's ataxia.

    For more information please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02255435

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    FA – COMS – Currently Enrolling

    This is a long-term study of the natural progression of disease in Friedreich’s Ataxia (FA)

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    Retrotope RTMOTION – Ongoing Not Enrolling

    This is a study of a wearable gait device detecting movement in 3D in patients with movement disorders.

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    SCA - IVIG 2014 – Currently Enrolling

    The purpose of this study is to learn how Intravenous Immune Globulin (IVIG) will affect Spinocerebellar Ataxia (SCA) symptoms and how it will affect motor and nervous system function in participants Subtypes of SCA to be examined will include SCA types 1, 2, 3, 6, 10 and 11.

    For more information please visit the website at:

    https://clinicaltrials.gov/ct2/show/NCT02287064

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    FA - Gait and Balance – Currently Enrolling

    The purpose of this study is to assess gait and balance changes in Friedreich’s ataxia patients over the course of 12 months and correlate these changes to clinical measures of ataxia.

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    PSP - BMS CN002-003 – Currently Enrolling

    The goal of this study is to evaluate the safety and tolerability of multiple doses of BMS-986168 in patients with PSP.

    For more information please visit the website at:

    https://clinicaltrials.gov/ct2/show/NCT02460094

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    SCA - BHV4157-201 (Biohaven) – Start-up/Pending

    The purpose of this study is to compare the efficacy of BHV-4157 versus placebo on ataxia symptoms in subjects with spinocerebellar ataxia (SCA).

    For more information please visit the website at:

    https://clinicaltrials.gov/ct2/show/NCT02460094

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    PSP - Abbvie M15-562 – Start-uo/Pending

    The purpose of this study is to assess the efficacy and long term safety and tolerability of ABBV-8E12 for up to 52 weeks in subjects with progressive supranuclear palsy (PSP).

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    ET - Cavion ET – Start-up/Pending

    Pending

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    FA - EPI743-16-003 (new PM) – Start-up/Pending

    Pending

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    FA - RT001-005 (Extension) – Start-up/Pending

    Pending

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

  • Huntington’s Disease

    Enroll HD Enroll HD is an observational study for families effected by Huntington’s Disease. This study monitors how the disease materializes and changes over time in different individuals. This study is open to people with HD, as well as, those who are at-risk. The Enroll HD study is intended to speed up discoveries and develop new therapies for Huntington’s Disease. For more information on this study please visit the Enroll-HD’s website at: www.enroll-hd.org To enroll in this study at USF please contact Clinical Coordinator Kelly Elliott at (813)974-0527
    Legato The Legato-HD trial evaluates the effect of the varying dosages of the investigational drug Laquinimod after a 12 month period of administration. The investigational drug, Laquinimod, is being studied to gage its effects on symptoms of HD, including abnormal movement, memory issues, and emotional conditions. For more information on this study please visit the Legato Huntington Study Group’s website at: http://huntingtonstudygroup.org/current-clinical-trials/legato-hd-trial/ To enroll in this study at USF please contact Clinical Coordinator Kelly Elliott at (813)974-0527
  • Multiple Sclerosis

    Affinity Ongoing - Not currently enrolling 2017-preset

     This clinical trial is a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies    For more information please call Angela Aungst at (813)974-6378
    ARISE Closed 2016-2019  The ARISE clinical trial is evaluating the safety and efficacy of an investigational drug to determine its effects on daytime sleepiness, tiredness, fatigue, and routine functioning in people with Idiopathic Hypersomnia and Narcolepsy without cataplexy. For more information on this study please visit the website at: http://www.arisestudies.com/index.html For more information please call Angela Aungst at (813)974-6378 
    Biotin Ongoing - not currently enrolling  This is a randomized double blind placebo controlled study that is evaluating the effect of MD1003 in progressive multiple sclerosis   For more information please call Angela Aungst at (813)974-6378
    BTKI Ongoing - not currently enrolling 2019-present This is a Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis   For more information please call Angela Aungst at (813)974-6378 
    Click-MS Enrolling  2019-Present Claudribine tablets: Observational evaluation of effectiveness and patient-reported outcomes in suboptimally controlled patients previously taking injectable disease-modifying drugs for relapsing forms of Multiple Sclerosis   For more information please call Angela Aungst at (813)974-6378 
    Chords CLOSED 2016-2019  The purpose of the clinical trial CHORDS is to evaluate the effectiveness and safety of the investigational drug Ocrelizumab in patients with relapsing remitting multiple sclerosis who have had a suboptimal response to an adequate course of disease-modifying treatments. For more information on this study please visit the website at: http://www.gene.com/media/press-releases/14609/2015-10-08/genentechs-ocrelizumab-first-investigati For more information please call Angela Aungst at (813)974-6378
    COMB-ASCLEPIOS Ongoing-not currently enrolling 2016-present The purpose of this study is to compare the efficacy and safety of Ofatumumab and Teriflunomide in patients with relapsing multiple sclerosis.  For more information please call Angela Aungst at (813)974-6378 
    COMB-POLOS ongoing 2018-present The purpose of this study is to compare the equivilance of subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult patients with relapsing multiple scleroris
      For more information please call Angela Aungst at (813)974-6378  
    COMB-ALITHIOS  ongoing-not currently enrolling 2018-present This is an extension study of the COMB-ASCLEPIOS study and the COMB-POLOS study which is evaluating the long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis   For more information please call Angela Aungst at (813)974-6378 
    CONSONANCE ongoing-not currently enrolling 2018-present This is an Open-label, single-arm 4-year study evaluating effectiveness and safety of ocrelizumab treatment in patients with Progressive Multiple Sclerosis
      For more information please call Angela Aungst at (813)974-6378
    LEM-COG Ongoing-not currently enrolling 2016-present  This clinical trial is a prospective 24 month observational study to evaluate neurocognitive function and safety in patient with relapsing MS who are initiating LEMTRADA treatment in routine clinical practice. To enroll in this study please contact Angela Aungst at (813)974-6378
    MASTER-2 enrolling 2019-Present Cladribine tablets: Observational evaluation of effectiveness and patient-reported outcomes in suboptimally controlled patients previously taking oral disease-modifying drugs for relapsing forms of multiple sclerosis
      To enroll in this study please contact Angela Aungst at (813)974-6378
    SunPharma CLOSED 2016-2017 This clinical trial is a placebo-controlled randomized withdrawal evaluation of the efficacy and safety of Baclofen ER Capsules in subjects with spasticity due to MS. For more information on this study please visit the Sun Pharmaceutical website at: http://www.sunpharma.com/ To enroll in this study please contact Angela Aungst at (813)974-6378
    ML29972 CLOSED   2016-2017 This trial is an open-label, multicenter, expanded access program for Ocrelizumab in patients with primary progressive multiple sclerosis. For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02807285 To enroll in this study please contact Angela Aungst at (813)974-6378
    NOVA Ongoing - Not currently enrolling 2019-Present A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment
      For more information please call Angela Aungst at (813)974-6378
    NMO CLOSED 2018-2019 This is a Double-masked, Placebo-controlled Study withOpen-label Period to Evaluate the Efficacy and Safety ofMEDI-551 in Adult Subjects with Neuromyelitis Optica andNeuromyelitis Optica Spectrum Disorders
      For more information please call Angela Aungst at (813)974-6378
    OCARINA Not enrolling yet   A Phase 1B, Open-label, Multi-cener study to investigate the pharmakinetics, safety, and tolerability of subcutaneous ocrelizumab administration in patients with multiple scleroris
      To enroll in this study please contact Angela Aungst at (813)974-6378
    ENDORSE CLOSED   This trial is a dose-blind study to determine the long-term safety and efficacy of two doses of BG00012 Monotherapy in subjects with relapsing-remitting Multiple Sclerosis. For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT00835770 For more information please call Angela Aungst at (813)974-6378
    EFFECT CLOSED  This clinical study is characterizing real-world clinical outcomes in patients with relapsing-remitting MS treated with disease modifying therapies (Tecfidera, Copaxone, Aubagio,or Gilenya) For more information please call Angela Aungst at (813)974-6378
    ENSEMBLE ongoing - not currently enrolling 2017-Present This is an open-label, single-arm study evaluating the effectivenss and safety of ocrelizumab in patients with early stage relapsing remitting multiple sclerosis
      For more information please call Angela Aungst at (813)974-6378
    ENSEMBLE PLUS ongoing-not currently enrolling 2019- present
    This is a sub-study of the ENSEMBLE trial that is evaluating the safety of shorter infusion of ocrelizumab in patients with early stage relapsing remitting multiple sclerosis
      For more information please call Angela Aungst at (813)974-6378
    ESTEEM Ongoing This study is collecting information in safety and documenting the drug utilization of Tecfidera (Dimethyl Fumarate) when used in routine medical practice in the treatment of MS. For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02047097 For more information please call Angela Aungst at (813)974-6378
    EXCHANGE enrolling 2019 - Present
    This clinical trial is a  6-month open label, multicenter Phase IIIb study that is Exploring the safety and tolerability of conversion from oral or injectable disease modifying therapies to dosetitrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis
      To enroll in this study please contact Angela Aungst at (813)974-6378
    EXPAND Ongoing – Not Currently Enrolling This clinical trial is a treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive MS. For more information on this study please visit the website at: www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients For more information please call Angela Aungst at (813)974-6378
    Ocre-Up enrolling 2018-Present A single-center prospective measurement of upper extremity function in multiple sclerosis patients with advanced disability treated with Ocrevus™
    For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT03562975?term=ocre-up&rank=1
    To enroll in this study please contact Angela Aungst at (813)974-6378
    OPERA Ongoing – Not Currently Enrolling This is a group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon Beta-1A (Rebif) in patients with relapsing MS. For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT01412333 For more information please call Angela Aungst at (813)974-6378
    OPERA II Ongoing - Not Currently enrolling  Parallel group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon Beta-1A (Rebif) in patients with relapsing MS. For more information please call Angela Aungst at (813)974-6378
    OPTIMUM ongoing - not currently enrolling 2015-Present Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis   For more information please call Angela Aungst at (813)974-6378
    OPTIMUM-LT ongoing - not currently enrolling 2017-Present Multicenter, non-comparative extension to OPTIMUM, to investigate the long-term safety, tolerability, and control of disease of ponesimod in subjects with relapsing multiple sclerosis   For more information please call Angela Aungst at (813)974-6378
    OPTIONS enrolling 2017-Present
    A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis
    For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT03126760?term=rrms%2C+acthar+gel&rank=2
    To enroll in this study please contact Angela Aungst at (813)974-6378
    PASS enrolling 2017-Present A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis
      To enroll in this study please contact Angela Aungst at (813)974-6378
    PROCLAIM CLOSED  An open-label study to access the effects of BG00012 on Lymphocyte subsets in subjects with relapsing-remitting MS. For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT00686959 For more information please call Angela Aungst at (813)974-6378
    Protract CLOSED  This is a retrospective study and a patient real-world clinical, neurological, tolerability, and safety outcomes for Tecfidera and Rebif. For more information please call Angela Aungst at (813)974-6378
    SunPharma CLOSED  This is a clinical evaluation of the safety of Baclofen ER Capsules (GRS) when administered once daily to subjects with spasticity due to MS. For more information on this study please visit the website at: http://www.sunpharma.com/ For more information please call Angela Aungst at (813)974-6378
    SunPharma CLOSED 2016-2017
    This clinical trial is a placebo-controlled randomized withdrawal evaluation of the efficacy and safety of Baclofen ER Capsules in subjects with spasticity due to MS.
    For more information on this study please visit the Sun Pharmaceutical website at: http://www.sunpharma.com/
    For more information please call Angela Aungst at (813)974-6378
    TOPAZ Ongoing - Not currently enrolling This is a long-term follow-up study for MS patients who have completed the alemtuzumab Extension Study (CAMMS03409) For more information on this study please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02167945 For more information please call Angela Aungst at (813)974-6378
    PRIME-COG enrolling 2018-Present
    The purpose of this study is to assess relationships between cognitive function and brain atrophy in MS patients
      To enroll in this study please contact Angela Aungst at (813)974-6378
    ULTIMATE ongoing - not currently enrolling 2017-Present This is a randomized, multi-center, double-blinded, doubledummy, active-controlled study that is primarily designed to assess the annualized relapse rate and safety/tolerability of ublituximab/oral placebo as compared to teriflunomide/IV placebo in subjects with RMS.
      For more information please call Angela Aungst at (813)974-6378
    Veloce Ongoing - Not currently enrolling This is a phase IIIb, study to evaluate the effects of Orcelizumab on immune responses in patients with relapsing forms of MS. For more information please call Angela Aungst at (813)974-6378
  • Neuromuscular Disease

    CSL Behring – CIDP (Chronic Inflammatory Demyelinating Polyneuropathy)
    Currently Enrolling
    A study of subcutaneous immunoglobulin as chronic treatment for patients with chronic inflammatory demyelinating polyneuropathy   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
    Axsome Therapeutics, Inc. – CRPS (Complex Regional Pain Syndrome)
    Currently Enrolling
    CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zoledronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
    Grifols – MG (Myasthenia Gravis)
    Currently Enrolling
    A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
    Grifols – MG (Myasthenia Gravis)
    Currently Enrolling
    A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
    Alexion – MG (Myasthenia Gravis)
    Ongoing
    Not Enrolling
    A Phase III, Open-label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
    arGEN-X BVBA – MG (Myasthenia Gravis)
    Pending CTA
    A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness   To enroll in this study at USF please contact Brittany Harvey at 813-974-9413.
  • Parkinson’s Disease

    Biotie

    This clinical trial to an adjunctive medication to reduce end of dose wearing off in PD patients (Tozadenant). Placebo controlled with Open Label Extension

    For more information please visit the website at: www.biotie.com

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Civitas

    This clinical trial to an adjunctive medication to reduce end of dose wearing off in PD patients (Inhaled Levodopa). Open Label Extension trial

     

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Cynapsus

    This clinical trial to an adjunctive medication to reduce end of dose wearing off in PD patients (Sublingual ApoMorphine).Open Label Extension trial.

    For more information please visit the website at: www.sunovion.com

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Intec

    This clinical trial to evaluate the efficacy of an Accordion Pill style medication with less doses and reduce OFF time. Placebo controlled with Open Label Extension

     

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Pfizer

    This clinical trial aims to reduce OFF time and reduce Sinemet dosing. Placebo Controlled with an Open Label Extension

    For more information please visit the website at: www.pfizer.com

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Pfizer

    This clinical trial is for Early PD patients on MAOB medication. Placebo Controlled.

     

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    MJFF

    Observational trial for people of Ashkenzani Jewish Decent or first degree relatives with PD

    For more information please visit the website at: www.michaeljfox.org

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Lundbeck

    Medication to control Orthostatic Hypotension in Parkinson's Disease patients. Placebo Controlled

    For more information please visit the website at: www.lundbeck.com

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    NIH

    Early PD patients within 3 years diagnosis currently not on treatment. Placebo Controlled.

     

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Impax

    This trial is to assess the Pharmacokeinetics in patients with Advanced Parkinson's Disease

    For more information please visit the website at: www.impaxpharma.com

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Neuroderm

    Sinemet delivered through a subcutaneous infusion as an adjunct to oral Sinemet

    For more information please visit the website at www.neuroder.com

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    Sunovion

    Medication to control halluncinations in patients with Advanced Parkinson's Disease. Placebo controlled

    For more information please visit the website at www.sunovion.com

    To enroll in this study at USF please contact Claudia Rocha at 813-396-0757

    PD and ED - Sagene2014 – Currently Enrolling

    The purpose of this study is to see if selegiline and tadalafil (generic for Cialis®) results in an improvement in Erectile dysfunction (ED) in male patients with Parkinson's disease (PD) and moderate ED. Male PD patients who have an incomplete response to tadalafil alone will be given both medications to see if the addition of selegiline improves ED symptoms more than tadalafil alone. It is common practice for a medical doctor to prescribe these two drugs to a patient like you. However, there have been no studies conducted to examine the effects of these medications when taken together.

    For more information please visit the website at: https://clinicaltrials.gov/ct2/show/NCT02225548

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    PD - Emory-LRRK2 – Currently Enrolling

     

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    PD - B7601011 (Pfizer Early PD) – Currently Enrolling

    This study is intended to evaluate the effect of PF-06649751 on safety and efficacy in a population of patients with early stage Parkinson’s disease.

     

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

    PD – ND0612H Clinical Trial for a liquid carbidopa/levodopa formulation is delivered by subcutaneous infusion via a small pump worn on a belt or placed in a pocket to alleviate motor fluctuations in people with Parkinson’s Disease. This study is a one year open-label study in which all patients receive ND0612.Given the very high level of interest in this therapy the enrollment period is expected to be only a few weeks, probably only extending until the end of August.   To enroll in this study at USF please contact Leigh Harrell at 813-396-0786.

    PSP - BMS CN002-004 (extension) – On-going Currently Not Enrolling

    The goal of this study is to evaluate long-term safety and pharmacokinetics during multiple IV infusions of BMS-986168 in PSP patients. In addition to demonstrating multiple dose long-term safety and tolerability, BMS-986168 is expected to lower free eTau concentrations in the CSF of these patients. This study will also evaluate the progression of PSP patients treated with BMS-986168 on pharmacodynamic (PD) endpoints as well as clinical, magnetic resonance imaging (MRI), and eye tracking assessments.

    For more information please visit the website at:

    https://clinicaltrials.gov/ct2/show/NCT02658916

    To enroll in this study at USF please contact Jessica Shaw at 813-974-1414

  • Stroke

    PISCES III

    PISCES III is a clinical research study to determine if a study drug, which is made from stem cells, will help improve function in people who have limited movement in their arms and/or legs 6–12 months after having an ischemic stroke. Ischemic stroke is the most common type of stroke and occurs when a blood vessel, which supplies blood to the brain, is blocked by a clot.

    For more information on this study and to take the eligibility questionnaire please visit the website at: http://pisces3.org/

    To enroll in this study at USF please contact Tara McTigue at (813)259-0826

    ARCADIA

    The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokesand atrial cardiopathy to see which is better at prevention of future strokes.

    For more information on this study please visit this website: https://clinicaltrials.gov/ct2/show/NCT03192215

    To enroll in this study at USF please contact Tara McTigue at (813)259-0826

  • Epilepsy

    UCB EP0088

    Multicenter 1-Year observational study of patients who are initiating Brivaracetam. The overall objective of this study is to inform clinical through real-life experience to achieve better patient outcomes using Brivaracetam.

     

    To enroll in this study at USF please contact Tara McTigue at 813-259-8577 or Tmctigue@health.usf.edu

    OPUS

    Currently Enrolling
    The purpose of this study is to see how well natalizumab works in subjects with focal epilepsy (when seizures start in a region of the brain). Subjects who participate in this study have seizures that did not fully improve after taking 2 or more anti-epileptic drugs (AEDs) and that still occur frequently. This study will see if the number of seizures subjects experience decreases while taking the study drug and how safe the study drug is. The study drug will be given as an additional therapy alongside the subjects’ usual AEDs.

    For more information on this study please visit the website:

    http://clinicaltrials.gov/ct2/show/NCT03283371

    To enroll in this study at USF please contact Tara McTigue at (813)259-0826
    Brain Sentinel
    Currently Enrolling
    The Brain Sentinel® Seizure Monitoring and Alerting System has been cleared by the US Food and Drug Administration (FDA) to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures, and to provide an alarm to alert caregivers of certain movements of the body that could be associated with a GTC seizure. GTC seizures are the most common type of seizures. They are seizures that affect the electrical activity of the entire brain. sEMG is a technique use to look at electrical activity of muscle and skeletal groups. The purpose of this research is to determine the System’s performance, its ease of use for patients and physicians, and to collect observational data related to the clinical utility of the System in an outpatient setting in patients with a history of motor seizures   To enroll in this study at USF please contact Tara McTigue at (813)259-0826
    Cavion Absence Epilepsy
    Currently Enrolling
    This is a research study of an experimental drug called CX-8998 for adolescents and young adults who have absence epilepsy. The purpose of this study is to learn whether CX-8998 has any side effects when given for 27 days in total daily doses of 4 milligrams (mg) to 20 mg per day. For more information on this study please visit this website: https://clinicaltrials.gov/ct2/show/NCT03406702 To enroll in this study at USF please contact Tara McTigue at (813)259-0826